Key facts
- This page summarizes David W. Gryska's Form 4 filing for Forte Biosciences, Inc. (FBRX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Mar 2025, 16:51.
David W. Gryska - 20 Mar 2025 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)
- Reporting relationship
- Director
- Issuer ticker
- FBRX
- Reported as of
- 20 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2025, 16:51:12 UTC
- Prior SEC filing
- 05 Dec 2024
- Next SEC filing
- 16 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David W. Gryska filed Form 4 for Forte Biosciences, Inc. (FBRX) on 21 Mar 2025.
Change
- Previous filing in this sequence was filed on 05 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FBRX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +31,000
- Change %
- Price
- $0.000000
- Shares after
- 31,000
- Date
- 20 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,000
- Exercise price
- $7.54
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three (3) year period such that the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. "Date of Grant" shall mean March 20, 2025.